Prognosis of cancers associated with venous thromboembolism.

By Henrik T Sørensen, L. Mellemkjær, J. Olsen, J. Baron. New England Journal of Medicine, 2000

1,611 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/962c6e224f5d9c0e52fd229875198560a23da041

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. H. Sørensen
2. M. Schmidt

Citations in the corpus

• The Effects of a Smoking Cessation Intervention on 14.5-Year Mortality (2005, background): “It is unclear what risks are for various types and stages of cancer.(4,5) In the last 2 decades, several hereditary risk factors for venous thrombosis have been identified.”
• Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients (2008, background): “Thromboembolism is a leading cause of death in cancer patients(3) and cancer patients who develop VTE have a significantly worse survival.(4,5) Cancer patients with VTE also suffer a higher rate of both bleeding complications and recurrent VTE.”
• American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. (2021, background): “Patients with cancer are at greater risk for VTE than is the general population, resulting in considerable morbidity, mortality, and costs.(13,15-23) Approximately 20% of all cases of VTE occur in”
• Epidemiology of cancer-associated venous thrombosis. (2013, neutral): “In a large Danish population-based study, patients diagnosed with cancer at the time of venous thrombosis were matched to control cancer patients without venous thrombosis, based on age, gender, type of cancer, and year of diagnosis.(50) The 1-year survival rate for the group with cancer and venous ”
• Incidence of venous thromboembolism and its effect on survival among patients with common cancers. (2006, neutral): “Prostate 50 926 0 70 33 383 (66) 7041 (14) 3515 (7) 6987 (14) Breast 44 744 99 62 27 014 (60) 13 629 (30) 2029 (5) 2072 (5) Lung 45 215 45 69 6558 (15) 8775 (19) 22 486 (50) 7396 (16) Colon/rectum 32 157 50 71 10 623 (33) 12 766 (40) 6409 (20) 2359 (7) Melanoma 9930 44 55 8065 (81) 431 (4) 466 (5) 9”
• The Danish Civil Registration System as a tool in epidemiology (2014, methodology): “Linking the CRS, the Danish National Patient Registry, and the Danish Cancer Registry, one study examined the survival of patients who received a diagnosis of cancer at the same time as or after an episode of venous thromboembolism [30].”
• Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. (2002, background): “Patients with cancer and venous thromboembolism have a 3-fold lower survival at 1 year than patients with cancer who do not have venous thromboembolism.(3) The increased mortality rate observed in cancer patients with venous thromboembolism may result from a more advanced cancer state(3) but can als”